Compare Stocks → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CVACNASDAQ:GHRSNYSE:NUVBNASDAQ:VERV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$2.99+1.7%$2.98$2.21▼$12.36$669.40M2.51809,461 shs417,167 shsGHRSGH Research$12.08+3.3%$10.45$5.05▼$14.64$628.52M0.8125,952 shs76,680 shsNUVBNuvation Bio$3.19+0.3%$2.74$0.95▼$4.16$695.58M1.421.21 million shs1.54 million shsVERVVerve Therapeutics$6.16-3.9%$10.78$5.84▼$21.42$516.95M1.941.22 million shs884,681 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac-5.91%+16.87%-3.76%-17.04%-64.26%GHRSGH Research+0.09%+8.74%+4.94%+53.21%+29.17%NUVBNuvation Bio-1.24%+7.80%-3.34%+96.30%+90.42%VERVVerve Therapeutics0.00%+2.40%-24.77%-44.07%-60.53%$21,000 in profits in six weeks? (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac3.9158 of 5 stars3.04.00.04.92.50.00.6GHRSGH Research1.1478 of 5 stars3.51.00.00.02.90.80.0NUVBNuvation Bio2.7821 of 5 stars4.53.00.00.00.03.30.0VERVVerve Therapeutics2.4489 of 5 stars3.40.00.00.02.14.21.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac2.00Hold$8.33178.71% UpsideGHRSGH Research3.00Buy$36.67203.53% UpsideNUVBNuvation Bio3.00Buy$6.60106.90% UpsideVERVVerve Therapeutics2.75Moderate Buy$33.00435.71% UpsideCurrent Analyst RatingsLatest NUVB, CVAC, GHRS, and VERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2024GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.005/6/2024GHRSGH ResearchCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $31.004/25/2024CVACCureVacLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/25/2024CVACCureVacSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $4.004/17/2024NUVBNuvation BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.004/8/2024VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/5/2024CVACCureVacGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral4/3/2024VERVVerve TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $40.003/28/2024NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/27/2024NUVBNuvation BioJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$1.40 ➝ $10.003/26/2024NUVBNuvation BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$58.18M11.51N/AN/A$2.50 per share1.20GHRSGH ResearchN/AN/AN/AN/A$4.94 per shareN/ANUVBNuvation BioN/AN/AN/AN/A$2.76 per shareN/AVERVVerve Therapeutics$11.76M43.96N/AN/A$7.31 per share0.84Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac-$281.58MN/A0.00N/AN/A-483.85%-41.87%-29.65%6/4/2024 (Estimated)GHRSGH Research-$35.59M-$0.62N/AN/AN/AN/A-14.31%-13.87%8/28/2024 (Estimated)NUVBNuvation Bio-$75.80M-$0.34N/AN/AN/AN/A-12.21%-11.89%5/9/2024 (Estimated)VERVVerve Therapeutics-$200.07M-$3.12N/AN/AN/A-1,701.70%-39.33%-30.92%5/20/2024 (Estimated)Latest NUVB, CVAC, GHRS, and VERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023GHRSGH Research-$0.20-$0.21-$0.01-$0.21N/AN/A2/29/2024Q4 2023NUVBNuvation Bio-$0.10-$0.06+$0.04-$0.06N/AN/A2/27/2024Q4 2023VERVVerve Therapeutics-$0.83-$0.69+$0.14-$0.69$3.95 million$5.14 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.072.572.43GHRSGH ResearchN/A24.4924.49NUVBNuvation BioN/A44.1144.11VERVVerve TherapeuticsN/A17.2417.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%GHRSGH Research56.90%NUVBNuvation Bio61.67%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipCVACCureVacN/AGHRSGH ResearchN/ANUVBNuvation Bio36.09%VERVVerve Therapeutics21.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac1,172223.88 millionN/AOptionableGHRSGH Research4952.03 millionN/AOptionableNUVBNuvation Bio51218.05 million139.35 millionOptionableVERVVerve Therapeutics25583.92 million65.96 millionOptionableNUVB, CVAC, GHRS, and VERV HeadlinesSourceHeadlineVerve moves forward with backup base editing therapybiopharmadive.com - May 7 at 5:47 PMVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102finance.yahoo.com - May 7 at 9:47 AMVerve Therapeutics (NASDAQ:VERV) Trading 7.8% Higher americanbankingnews.com - May 5 at 4:34 AMVerve Therapeutics (NASDAQ:VERV) Trading Up 7.8%marketbeat.com - May 3 at 9:33 PMVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 3 at 4:01 PMVerve Therapeutics (NASDAQ:VERV) Reaches New 12-Month Low at $5.93americanbankingnews.com - May 3 at 5:20 AMVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $5.93marketbeat.com - May 1 at 12:28 PMVerve Therapeutics (NASDAQ:VERV) Reaches New 1-Year Low at $6.05americanbankingnews.com - April 27 at 5:32 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 25 at 5:15 PMVerve Therapeutics (NASDAQ:VERV) Hits New 52-Week Low at $6.05marketbeat.com - April 25 at 3:44 PMSumitomo Mitsui Trust Holdings Inc. Grows Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)marketbeat.com - April 21 at 5:16 AMFederated Hermes Inc. Purchases 1,448,003 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)marketbeat.com - April 20 at 7:16 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 19 at 4:00 AMGV’s Newest Life Sciences General Partner Pursues Precision Treatmentswsj.com - April 18 at 9:55 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 18 at 8:00 AMVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77msn.com - April 18 at 12:03 AMVerve Therapeutics (NASDAQ:VERV) Stock Price Down 2.9%marketbeat.com - April 17 at 12:20 PMVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $7.26marketbeat.com - April 15 at 2:48 PMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 13 at 8:00 PMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 13 at 6:00 AMIMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 12 at 4:30 AMTop 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarterbenzinga.com - April 11 at 8:46 AMCRISPR-based innovations drove $21 billion in pharmaceutical licensing deals over five years: GlobalDatahealth.economictimes.indiatimes.com - April 10 at 9:48 AMBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recoverymarkets.businessinsider.com - April 9 at 8:55 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCureVacNASDAQ:CVACCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.GH ResearchNASDAQ:GHRSGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Nuvation BioNYSE:NUVBNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Verve TherapeuticsNASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.